Phase 2 Start
ONC: Phase 2 Start: A Phase 1/2a, Open-Label, Dose Finding and Expansion Study to Investigate the Safety, Tolerability,
October 1, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- October 1, 2026
- Company
- BeOne Medicines Ltd. (ONC)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 2 Start~month
Phase 2 Start: A Phase 1/2a, Open-Label, Dose Finding and Expansion Study to Investigate the Safety, Tolerability,
- Company
- BeOne Medicines Ltd. (ONC)
- Indication
- Acute Myeloid Leukemia; B-cell Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia